Elly L van der Veen
Overview
Explore the profile of Elly L van der Veen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
450
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
van de Donk P, Wind T, Hooiveld-Noeken J, van der Veen E, Glaudemans A, Diepstra A, et al.
Eur J Nucl Med Mol Imaging
. 2021 Jun;
48(13):4369-4376.
PMID: 34076745
Purpose: Immune checkpoint inhibitors can induce a T cell-mediated anti-tumor immune response in patients with melanoma. Visualizing T cell activity using positron emission tomography (PET) might allow early insight into...
2.
Li W, Wang Y, Rubins D, Bennacef I, Holahan M, Haley H, et al.
Mol Imaging Biol
. 2020 Oct;
23(2):250-259.
PMID: 33104972
Purpose: Programmed cell death-1 receptor (PD-1) and its ligand (PD-L1) are the targets for immunotherapy in many cancer types. Although PD-1 blockade has therapeutic effects, the efficacy differs between patients....
3.
van der Veen E, Giesen D, Pot-de Jong L, Jorritsma-Smit A, de Vries E, Lub-de Hooge M
J Immunother Cancer
. 2020 Oct;
8(2).
PMID: 33020241
Background: To better predict response to immune checkpoint therapy and toxicity in healthy tissues, insight in the in vivo behavior of immune checkpoint targeting monoclonal antibodies is essential. Therefore, we...
4.
Stutvoet T, van der Veen E, Kol A, Antunes I, de Vries E, Hospers G, et al.
J Nucl Med
. 2020 May;
61(12):1839-1844.
PMID: 32358092
F-BMS-986192, an adnectin-based human programmed cell death ligand 1 (PD-L1) tracer, was developed to noninvasively determine whole-body PD-L1 expression by PET. We evaluated the usability of F-BMS-986192 PET to detect...
5.
van der Veen E, Suurs F, Cleeren F, Bormans G, Elsinga P, Hospers G, et al.
J Nucl Med
. 2020 Mar;
61(9):1355-1360.
PMID: 32111688
Recently, -(4-F-fluorobenzoyl)-interleukin-2 (F-FB-IL2) was introduced as a PET tracer for T cell imaging. However, production is complex and time-consuming. Therefore, we developed 2 radiolabeled IL2 variants, namely aluminum F-fluoride-(restrained complexing...
6.
van der Veen E, Antunes I, Maarsingh P, Hessels-Scheper J, Zijlma R, Boersma H, et al.
EJNMMI Radiopharm Chem
. 2019 Oct;
4(1):15.
PMID: 31659562
Background: Molecular imaging of immune cells might be a potential tool for response prediction, treatment evaluation and patient selection in inflammatory diseases as well as oncology. Targeting interleukin-2 (IL2) receptors...
7.
Bensch F, van der Veen E, Lub-de Hooge M, Jorritsma-Smit A, Boellaard R, Kok I, et al.
Nat Med
. 2018 Nov;
24(12):1852-1858.
PMID: 30478423
Programmed cell death protein-1/ligand-1 (PD-1/PD-L1) blockade is effective in a subset of patients with several tumor types, but predicting patient benefit using approved diagnostics is inexact, as some patients with...
8.
van der Veen E, Bensch F, Glaudemans A, Lub-de Hooge M, de Vries E
Cancer Treat Rev
. 2018 Oct;
70:232-244.
PMID: 30308466
Cancer immunotherapy has led to impressive antitumor effects. However, not all patients respond to immunotherapy, serious toxicity can occur and combination therapy may be warranted. Strategies for rational early treatment...